InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Provention Biosciences shares are trending after reporting earnings. PRVB stock is also up 25% on hopes of FDA approval for teplizumab.
The post Why Is Provention Biosciences (PRVB) Stock Up 25% Today? appeared first on InvestorPlace.
More From InvestorPlace